
Monica E. Millner
Examiner (ID: 17239, Phone: (571)270-7507 , Office: P/3632 )
| Most Active Art Unit | 3632 |
| Art Unit(s) | 3632, 3508, 3627 |
| Total Applications | 1497 |
| Issued Applications | 1151 |
| Pending Applications | 94 |
| Abandoned Applications | 283 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15589493
[patent_doc_number] => 20200071281
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-05
[patent_title] => 1,4,5-SUBSTITUTED 1,2,3-TRIAZOLE ANALOGUES AS ANTAGONISTS OF THE PREGNANE X RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 16/679007
[patent_app_country] => US
[patent_app_date] => 2019-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679007
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/679007 | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor | Nov 7, 2019 | Issued |
Array
(
[id] => 18701295
[patent_doc_number] => 11787794
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Aminothiazole compounds and methods using same
[patent_app_type] => utility
[patent_app_number] => 16/676630
[patent_app_country] => US
[patent_app_date] => 2019-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19702
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16676630
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/676630 | Aminothiazole compounds and methods using same | Nov 6, 2019 | Issued |
Array
(
[id] => 17496452
[patent_doc_number] => 11285135
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-29
[patent_title] => KRAS G12C inhibitors and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 16/675121
[patent_app_country] => US
[patent_app_date] => 2019-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56038
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 388
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675121
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/675121 | KRAS G12C inhibitors and methods of using the same | Nov 4, 2019 | Issued |
Array
(
[id] => 17554849
[patent_doc_number] => 11311506
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Controlling biofilms with cyclopropanated fatty acids
[patent_app_type] => utility
[patent_app_number] => 16/670802
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 10837
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670802
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/670802 | Controlling biofilms with cyclopropanated fatty acids | Oct 30, 2019 | Issued |
Array
(
[id] => 17227063
[patent_doc_number] => 20210353619
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => TREATMENT FOR VENETOCLAX-RESISTANT AND VENETOCLAX-SENSITIVE ACUTE MYELOID LEUKEMIA
[patent_app_type] => utility
[patent_app_number] => 17/290649
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20927
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290649
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290649 | TREATMENT FOR VENETOCLAX-RESISTANT AND VENETOCLAX-SENSITIVE ACUTE MYELOID LEUKEMIA | Oct 29, 2019 | Abandoned |
Array
(
[id] => 16429422
[patent_doc_number] => 10829489
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-10
[patent_title] => Bicyclic heterocyclic derivatives
[patent_app_type] => utility
[patent_app_number] => 16/666550
[patent_app_country] => US
[patent_app_date] => 2019-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17035
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 230
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16666550
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/666550 | Bicyclic heterocyclic derivatives | Oct 28, 2019 | Issued |
Array
(
[id] => 17193123
[patent_doc_number] => 11161864
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-02
[patent_title] => Sting agonists
[patent_app_type] => utility
[patent_app_number] => 16/662980
[patent_app_country] => US
[patent_app_date] => 2019-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 73831
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 407
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16662980
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/662980 | Sting agonists | Oct 23, 2019 | Issued |
Array
(
[id] => 15828677
[patent_doc_number] => 20200129620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => Treatment Of Myopia And Other Ocular Conditions Using Singlet Oxygen Generated From Dyes Activated By Near-Infrared Light
[patent_app_type] => utility
[patent_app_number] => 16/661644
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25930
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661644
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/661644 | Treatment Of Myopia And Other Ocular Conditions Using Singlet Oxygen Generated From Dyes Activated By Near-Infrared Light | Oct 22, 2019 | Abandoned |
Array
(
[id] => 16970413
[patent_doc_number] => 11066373
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-20
[patent_title] => Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
[patent_app_type] => utility
[patent_app_number] => 16/599392
[patent_app_country] => US
[patent_app_date] => 2019-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 30
[patent_no_of_words] => 32673
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599392
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/599392 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2019 | Issued |
Array
(
[id] => 16704326
[patent_doc_number] => 10954246
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-23
[patent_title] => Compound of EOC315 Mod.I crystal form and preparation method thereof
[patent_app_type] => utility
[patent_app_number] => 16/599662
[patent_app_country] => US
[patent_app_date] => 2019-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 6033
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599662
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/599662 | Compound of EOC315 Mod.I crystal form and preparation method thereof | Oct 10, 2019 | Issued |
Array
(
[id] => 17193101
[patent_doc_number] => 11161842
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-02
[patent_title] => Bifunctional molecules for degradation of EGFR and methods of use
[patent_app_type] => utility
[patent_app_number] => 16/588750
[patent_app_country] => US
[patent_app_date] => 2019-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 9
[patent_no_of_words] => 36012
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 294
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16588750
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/588750 | Bifunctional molecules for degradation of EGFR and methods of use | Sep 29, 2019 | Issued |
Array
(
[id] => 17398227
[patent_doc_number] => 20220040317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/279752
[patent_app_country] => US
[patent_app_date] => 2019-09-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16528
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279752
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279752 | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | Sep 25, 2019 | Pending |
Array
(
[id] => 17074862
[patent_doc_number] => 11111247
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-07
[patent_title] => Pyrazolopyrimidine compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/580766
[patent_app_country] => US
[patent_app_date] => 2019-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40227
[patent_no_of_claims] => 48
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 2550
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580766
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/580766 | Pyrazolopyrimidine compounds and uses thereof | Sep 23, 2019 | Issued |
Array
(
[id] => 15451171
[patent_doc_number] => 20200038409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => AMINOPYRIMIDINYL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/580667
[patent_app_country] => US
[patent_app_date] => 2019-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580667
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/580667 | Aminopyrimidinyl compounds | Sep 23, 2019 | Issued |
Array
(
[id] => 17118719
[patent_doc_number] => 11129828
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-28
[patent_title] => Pyridazinone compounds and their use as DAAO inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/580095
[patent_app_country] => US
[patent_app_date] => 2019-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21257
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580095
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/580095 | Pyridazinone compounds and their use as DAAO inhibitors | Sep 23, 2019 | Issued |
Array
(
[id] => 17451917
[patent_doc_number] => 11266754
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-08
[patent_title] => Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/579133
[patent_app_country] => US
[patent_app_date] => 2019-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10867
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579133
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/579133 | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | Sep 22, 2019 | Issued |
Array
(
[id] => 18077353
[patent_doc_number] => 20220402965
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => STEROL ANALOGS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/277829
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -236
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277829
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/277829 | STEROL ANALOGS AND USES THEREOF | Sep 18, 2019 | Pending |
Array
(
[id] => 19210672
[patent_doc_number] => 11999720
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Pyrazolylacylpyrazoline compounds and method for treating pain
[patent_app_type] => utility
[patent_app_number] => 17/251473
[patent_app_country] => US
[patent_app_date] => 2019-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 14
[patent_no_of_words] => 15520
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251473
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/251473 | Pyrazolylacylpyrazoline compounds and method for treating pain | Sep 18, 2019 | Issued |
Array
(
[id] => 15768743
[patent_doc_number] => 20200115389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/573900
[patent_app_country] => US
[patent_app_date] => 2019-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36755
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573900
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/573900 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | Sep 16, 2019 | Abandoned |
Array
(
[id] => 17472407
[patent_doc_number] => 20220079911
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-17
[patent_title] => USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/274937
[patent_app_country] => US
[patent_app_date] => 2019-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29827
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274937
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/274937 | USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS | Sep 11, 2019 | Pending |